Tomasz Piotrowski1,2, Magdalena Fundowicz3, Mariola Pawlaczyk4. 1. Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland tomasz.piotrowski@wco.pl. 2. Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland. 3. 1st Radiotherapy Ward, Greater Poland Cancer Centre, Poznan, Poland. 4. Department of Geriatrics and Gerontology, Poznan University of Medical Sciences, Poznan, Poland.
Abstract
BACKGROUND/AIM: The aim of the study was to retrospectively assess the efficacy and toxicity of total skin electron beam therapy (TSEBT) in patients with primary cutaneous T-cell lymphoma (MF, mycosis fungoides) at various stages of development. PATIENTS AND METHODS: Treatment results of 40 patients with MF stage IB-III, treated between 2001 and 2015, were reviewed. Median total dose was 32 Gy, delivered to the entire skin surface. Median follow-up was 60 months. RESULTS: Clinical complete response was documented in 29 and partial response in 11 patients. The clinical response significantly influenced overall survival (OS) (p=0.002) and progression-free survival (PFS) (p<0.001). Mean OS was 76 months. Mean PFS was 48.9 months and current one- and two-year PFS were 67.5% and 55%, respectively. A statistically significant correlation was found between partial and total remission time and stages of the lymphoma (p=0.015). CONCLUSION: TSEBT is an efficient and well-tolerated palliative treatment for symptomatic primary cutaneous T-cell lymphoma. Copyright
BACKGROUND/AIM: The aim of the study was to retrospectively assess the efficacy and toxicity of total skin electron beam therapy (TSEBT) in patients with primary cutaneous T-cell lymphoma (MF, mycosis fungoides) at various stages of development. PATIENTS AND METHODS: Treatment results of 40 patients with MF stage IB-III, treated between 2001 and 2015, were reviewed. Median total dose was 32 Gy, delivered to the entire skin surface. Median follow-up was 60 months. RESULTS: Clinical complete response was documented in 29 and partial response in 11 patients. The clinical response significantly influenced overall survival (OS) (p=0.002) and progression-free survival (PFS) (p<0.001). Mean OS was 76 months. Mean PFS was 48.9 months and current one- and two-year PFS were 67.5% and 55%, respectively. A statistically significant correlation was found between partial and total remission time and stages of the lymphoma (p=0.015). CONCLUSION: TSEBT is an efficient and well-tolerated palliative treatment for symptomatic primary cutaneous T-cell lymphoma. Copyright
Authors: Lise M Lindahl; Maria R Kamstrup; Peter M Petersen; Johan Wirén; Morten Fenger-Grøn; Robert Gniadecki; Lars Iversen; Lena Specht Journal: Acta Oncol Date: 2011-07-08 Impact factor: 4.089
Authors: Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: Maria R Kamstrup; Lena Specht; Gunhild L Skovgaard; Robert Gniadecki Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-22 Impact factor: 7.038
Authors: Henrik Hauswald; Felix Zwicker; Nathalie Rochet; Matthias Uhl; Frank Hensley; Jürgen Debus; Klaus Herfarth; Marc Bischof Journal: Radiat Oncol Date: 2012-07-29 Impact factor: 3.481